Corrigendum to "Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies"
Saved in:
| Format: | Book |
|---|---|
| Published: |
SAGE Publishing,
2024-03-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_7da8b266efaf4f4ca19d1d7edfb6d75a | ||
| 042 | |a dc | ||
| 245 | 0 | 0 | |a Corrigendum to "Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies" |
| 260 | |b SAGE Publishing, |c 2024-03-01T00:00:00Z. | ||
| 500 | |a 2515-8163 | ||
| 500 | |a 10.1177/25158163241233831 | ||
| 546 | |a EN | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 690 | |a Neurosciences. Biological psychiatry. Neuropsychiatry | ||
| 690 | |a RC321-571 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Cephalalgia Reports, Vol 7 (2024) | |
| 787 | 0 | |n https://doi.org/10.1177/25158163241233831 | |
| 787 | 0 | |n https://doaj.org/toc/2515-8163 | |
| 856 | 4 | 1 | |u https://doaj.org/article/7da8b266efaf4f4ca19d1d7edfb6d75a |z Connect to this object online. |